NCT04521231 2026-03-06A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLAmgenPhase 1/2 Recruiting281 enrolled
NCT07134088 2026-01-29A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic LeukemiaAmgenPhase 1/2 Recruiting104 enrolled
NCT01499394 2026-01-21Caris Biorepository Research ProtocolCaris Science, Inc.Recruiting100,000 enrolled
NCT04623216 2025-10-16Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.NovartisPhase 1/2 Terminated24 enrolled 16 charts
NCT04506086 2025-05-18Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)AmgenPhase 4 Terminated10 enrolled 12 charts